Abstract
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies.
The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of patients with bronchiectasis. The inclusion criterion is a primary clinical diagnosis of bronchiectasis consisting of: 1) a clinical history consistent with bronchiectasis; and 2) computed tomography demonstrating bronchiectasis. Core exclusion criteria are: 1) bronchiectasis due to known cystic fibrosis; 2) age <18 years; and 3) patients who are unable or unwilling to provide informed consent.
The study aims to enrol 1000 patients by April 2016 across at least 20 European countries, and 10 000 patients by March 2020. Patients will undergo a comprehensive baseline assessment and will be followed up annually for up to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life. Data from the registry will be available in the form of annual reports. and will be disseminated in conference presentations and peer-reviewed publications.
The European Bronchiectasis Registry aims to make a major contribution to understanding the natural history of the disease, as well as guiding evidence-based decision making and facilitating large randomised controlled trials.
Abstract
The European Bronchiectasis Registry will recruit 10 000 patients over 5 years http://ow.ly/Ul7Pd
Footnotes
This article has been republished to update reference 22.
This article has supplementary material available from openres.ersjournals.com
Support statement: The European Multicentre Bronchiectasis Audit and Research Collaboration is a European Respiratory Society Clinical Research Collaboration and is part of the iABC consortium supported by the European Union Innovative Medicines Initiative. EMBARC has also received funding and support from the US COPD Foundation, Bayer HealthCare and Aradigm Corporation. Funding information for this article has been deposited with FundRef.
Conflict of interest: S. Masefield is an employee of the European Respiratory Society. Disclosures can be found alongside this article at openres.ersjournals.com
- Received October 29, 2015.
- Accepted November 2, 2015.
- Copyright ©ERS 2015
The content of this work is ©the authors or their employers. Design and branding are ©ERS 2015. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.